Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

被引:183
|
作者
Halbreich, U
Kinon, BJ
Gilmore, JA
Kahn, LS
机构
[1] SUNY Buffalo, Sch Med & Biomed Sci, Biobehav Program, Buffalo, NY 14214 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
hyperprolactinemia; schizophrenia; prolactin; antipsychotics; osteoporosis;
D O I
10.1016/S0306-4530(02)00112-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The neurologic processes involved in schizophrenia are complex and diverse and the mechanisms through which antipsychotic agents exert their effects have been only partly elucidated. Hyperprolactinemia is a common side effect of treatment with many antipsychotics and is particularly associated with conventional ('typical') agents as well as the atypical antipsychotic risperidone. In contrast, other atypical agents introduced over the last decade do not elevate prolactin levels. This article discusses the regulatory mechanisms involved in prolactin secretion, the physiologic role of prolactin, and the etiology of hyperprolactinemia. Elevated prolactin levels may play important roles, both direct and indirect, in various pathologic states, including breast cancer, osteoporosis, cardiovascular disorders, and sexual disturbances. Antipsychotic-induced hyperprolactinemia may be associated with similar clinical manifestations; these are examined with particular reference to patients with schizophrenia. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:53 / 67
页数:15
相关论文
共 50 条
  • [31] Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
    Huang, Yinglin
    Ma, Huan
    Wang, Yuan
    Peng, Miao
    Zhu, Gang
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 1395 - 1397
  • [32] Elevated TNFα Levels in Cerebrospinal Fluid of Patients With Schizophrenia
    Gallego, Juan
    Morell, Christopher
    Malhotra, Monika
    McNamara, Robert
    Lencz, Todd
    Malhotra, Anil
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S575 - S576
  • [33] Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
    Eiji Kirino
    Annals of General Psychiatry, 16
  • [34] Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
    Kirino, Eiji
    ANNALS OF GENERAL PSYCHIATRY, 2017, 16
  • [35] The association between prolactin concentration and aggression in female patients with schizophrenia
    Puljic, Kresimir
    Herceg, Miroslav
    Tudor, Lucija
    Pivac, Nela
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2021, 22 (04) : 301 - 309
  • [36] Overview of prolactin levels in patients with schizophrenia during antipsychotic therapy at HB. Saanin Mental Hospital Padang, Indonesia
    Hasni, Dita
    Surya, Bayu Eka
    Anissa, Mutiara
    Anggraini, Debie
    BALI MEDICAL JOURNAL, 2023, 12 (01) : 831 - 837
  • [37] An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate
    Einarson, Thomas R.
    Hemels, Michiel E. H.
    Nuamah, Isaac
    Gopal, Srihari
    Coppola, Danielle
    Hough, David
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (10) : 1322 - 1330
  • [38] Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients
    Segal, Michael
    Avital, Avi
    Berstein, Severina
    Derevenski, Andrei
    Sandbank, Sergio
    Weizman, Abraham
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (02) : 378 - 382
  • [39] Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients
    Esel, E
    Basturk, M
    Gonul, AS
    Kula, M
    Turan, MT
    Yabanoglu, I
    Sofuoglu, S
    PSYCHONEUROENDOCRINOLOGY, 2001, 26 (06) : 641 - 647
  • [40] Managing antipsychotic-related sexual dysfunction in patients with schizophrenia
    Silva, Carlos
    Rebelo, Marta
    Chendo, Ines
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (12) : 1147 - 1155